Peer-reviewed veterinary case report
Intranasal insulin administration shows limited tau-targeted effects in early-stage APP/PS1 Alzheimer's mice.
- Journal:
- Neuroscience letters
- Year:
- 2025
- Authors:
- Mao, Yan Fang et al.
- Affiliation:
- Department of Neurology · China
- Species:
- rodent
Abstract
Brain insulin signaling deficits contribute to multiple pathologicalfeatures of Alzheimer's disease (AD).Intranasal insulin has demonstrated therapeutic potential, but its underlying mechanisms remain unclear. This study investigated whether intranasal insulinmodulates tau pathology in early-stage APPswe/PS1dE9 (APP/PS1) mice.After six weeks of treatment, no significant changes in total or phosphorylated tau levels were observed. However, there was a trend toward improvement in dysregulated signaling pathways associated with tau kinases. These findings suggest that the protective effect of nasal insulin in early AD may not primarily be against tau-related neurotoxicity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/40759310/